You are here: Industry Insights > Bristol-Myers

News List

Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal fiercepharma
January 08, 2019
It’s not only Celgene investors who are set for a big payoff with this week’s $74 billion sale to Bristol-Myers Squibb. Thanks to brand-new severance agreements inked days ahead of the deal announcement, its top executives could reap hefty gains, too.
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory? fiercepharma
January 08, 2019
Bristol-Myers Squibb’s Thursday announcement that it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the return has industry watchers wondering which company wil
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory? fiercepharma
January 08, 2019
Bristol-Myers Squibb’s Thursday announcement that it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the return has industry watchers wondering which company wil
FDA approves Bristol-Myers’ Sprycel to treat children with Ph+ ALL pharmaceutical-technology
January 04, 2019
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s Sprycel (dasatinib) drug for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL).....
Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer fiercebiotech
December 25, 2018
Bristol-Myers Squibb is tapping Eisai spinoff H3 Biomedicine and its RNA-splicing technology for a multiyear research partnership....
CHMP approve Bristol-Myers Squibb's Sprycel for paediatric patients with Ph+ ALL pharmafile
December 18, 2018
New Jersey-based firm Bristol -Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel...
Bristol-Myers and Vedanta to study combination therapy for cancer pharmaceutical-technology
December 12, 2018
Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate for the treatment of advanced or metastatic cancers.
Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial nasdaq
November 28, 2018
Bristol-Myers Squibb Company BMYannounced that the phase III CheckMate-451 study on immuno-oncology drug Opdivo in combination with Yervoy was unsuccessful....
Bristol-Myers reports positive results for Opdivo-Yervoy combination for advanced melanoma pharmaceutical-technology
October 23, 2018
Bristol-Myers Squibb has announced positive results from its trial into the efficacy of combination therapy with Opdivo (nivolumab) and Yervoy (ipilimumab), compared with either drug as a monotherapy, for patients with advanced melanoma.
Bristol-Myers Squibb tabs Christopher Boerner as chief commercial officer firstwordpharma
August 29, 2018
Bristol-Myers Squibb on Tuesday revealed that Christopher Boerner has been selected as chief commercial officer effective immediately.

Previous page 1 2 3 4 5 Next page